Shots:

• Regeneron is presenting results from studies evaluating Libtayo in indications NSCLC (P-I)- CSCC(P-I)- HCC(P-I)- BCC (P-II)- R/M Cervical Cancer (P-I)- Libtayo + RT+ GM-CSF for R/M HNSCC (P-I)
• Libtayo is a mAb targeting the immune checkpoint receptor PD-1 and was recently approved by the US FDA to treat locally advanced CSCC or mCSCC
• In 2015- Regeneron and Sanofi globally collaborated to develop Libtayo using Regeneron’s VelocImmune technology for treatment across various tumor types

Ref:  Regeneron | Image: Investors